There are 2949 resources available
Invited Discussant 886MO, 887MO, 888MO and 889MO
Presenter: Stefan Balabanov
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast
814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Presenter: Yvette Drew
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
815MO - The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Presenter: Benoit You
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
816MO - AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)
Presenter: Fabrice Lecuru
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA34 - Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials
Presenter: David O'Malley
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA35 - Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer
Presenter: Panagiotis Konstantinopoulos
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA36 - Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Presenter: Ana Oaknin
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1674MO - ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2
Presenter: Riyue Bao
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA81 - Keeping exhausted T-cells in check in COVID-19
Presenter: Pierre Van Mol
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast
LBA82 - Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study
Presenter: Melissa Bersanelli
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast